SCHEMBL1092123

SCHEMBL1092123

CCC(=O)c1ccc2c(c1)OCO2

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.81
MEN1 O00255 2/20 0.67
KMT2A Q03164 2/20 0.67
CTNNB1 P35222 6/20 0.64
WNT3A P56704 6/20 0.64
ALDH1A1 P00352 3/20 0.62
MAPK1 P28482 1/20 0.62
HPGD P15428 3/20 0.61
HDAC3 O15379 1/20 0.61
HDAC4 P56524 1/20 0.61
HDAC1 Q13547 1/20 0.61
HDAC7 Q8WUI4 1/20 0.61
HDAC2 Q92769 1/20 0.61
HDAC10 Q969S8 1/20 0.61
HDAC11 Q96DB2 1/20 0.61
HDAC8 Q9BY41 1/20 0.61
HDAC6 Q9UBN7 1/20 0.61
HDAC9 Q9UKV0 1/20 0.61
HDAC5 Q9UQL6 1/20 0.61
KDM4E B2RXH2 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29639737 1.00 ATM (0.81) ATMMEN1KMT2ACTNNB1WNT3A
SCHEMBL1092875 0.89 ATM (1.00) ATMCTNNB1WNT3AALDH1A1HPGD
SCHEMBL16369471 0.88 ATM (0.63) ATMMEN1KMT2ACTNNB1WNT3A
SCHEMBL31490470 0.86 HPGD (0.82) ATMMEN1KMT2ACTNNB1WNT3A
SCHEMBL14144501 0.86 ATM (0.87) ATMKMT2ACTNNB1WNT3AALDH1A1
SCHEMBL3924051 0.86 HPGD (0.82) ATMMEN1KMT2ACTNNB1WNT3A
SCHEMBL29458253 0.85 MEN1 (0.76) ATMMEN1KMT2ACTNNB1WNT3A
SCHEMBL2237626 0.85 MEN1 (0.76) ATMMEN1KMT2ACTNNB1WNT3A
SCHEMBL26940453 0.85 ATM (0.90) ATMKMT2ACTNNB1WNT3AALDH1A1
SCHEMBL6486626 0.84 CTNNB1 (0.66) ATMMEN1KMT2ACTNNB1WNT3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 125 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138964-A1 PREPARATION OF PHENETHYLAMINES AND CATHINONES AND STEREOISOMERS THEREOF AND PRECURSORS THEREOF TRANSCEND THERAPEUTICS, INC. (US) 2026-05-21 US claimed
EP-4605385-A1 PREPARATION OF PHENETHYLAMINES AND CATHINONES AND STEREOISOMERS THEREOF AND PRECURSORS THEREOF Transcend Therapeutics, Inc. (US) 2025-08-27 EP claimed
EP-4284789-B1 PROCESS FOR THE PREPARATION OF 3,4-METHYLENEDIOXYPROPIOPHENONE ENDURA SPA (IT) 2025-04-16 EP claimed
US-20240425471-A1 Process For The Preparation Of 3,4-Methylenedioxypropiophenone ENDURA S.P.A. (IT) 2024-12-26 US claimed
US-20240374558-A1 PREPARATION OF PHENETHYLAMINES AND CATHINONES AND STEREOISOMERS THEREOF AND PRECURSORS THEREOF TRANSCEND THERAPEUTICS, INC. (US) 2024-11-14 US claimed
US-20240327372-A1 PREPARATION OF PHENETHYLAMINES AND CATHINONES AND STEREOISOMERS THEREOF AND PRECURSORS THEREOF TRANSCEND THERAPEUTICS, INC. (US) 2024-10-03 US claimed
WO-2024086218-A1 PREPARATION OF PHENETHYLAMINES AND CATHINONES AND STEREOISOMERS THEREOF AND PRECURSORS THEREOF TRANSCEND THERAPEUTICS, INC. (US) 2024-04-25 WO claimed
CN-113490659-B Improved and economically viable process for preparing aryl ketones 安西娅芳香剂私人有限公司 2024-03-29 CN claimed
EP-4284789-A1 PROCESS FOR THE PREPARATION OF 3,4-METHYLENEDIOXYPROPIOPHENONE ENDURA S.p.A. (IT) 2023-12-06 EP claimed
CN-117015533-A Method for preparing 3, 4-methylenedioxypropiophenone 恩德拉股份公司 2023-11-07 CN claimed
US-11518727-B2 Commercially viable process for preparation of aryl ketones ANTHEA AROMATICS PRIVATE LIMITED (IN) 2022-12-06 US claimed
WO-2022162223-A1 PROCESS FOR THE PREPARATION OF 3,4-METHYLENEDIOXYPROPIOPHENONE ENDURA S.P.A. (IT) 2022-08-04 WO claimed
WO-2022161628-A1 PROCESS FOR THE PREPARATION OF 3,4-METHYLENEDIOXYPROPIOPHENONE ENDURA S.P.A. (IT) 2022-08-04 WO claimed
CN-114599355-A Method for treating psychological and cerebral diseases 马里兰大学巴尔的摩分校 2022-06-07 CN claimed
US-20220169588-A1 AN IMPROVED AND COMMERCIALLY VIABLE PROCESS FOR PREPARATION OF ARYL KETONES ANTHEA AROMATICS PRIVATE LIMITED (IN) 2022-06-02 US claimed
CN-113490659-A Improved and economically viable process for preparing aryl ketones 安西娅芳香剂私人有限公司 2021-10-08 CN claimed
EP-0290442-A4 PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS. CHEMEX PHARMACEUTICALS INC (US) 1990-07-03 EP claimed
EP-0290442-A1 PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS CHEMEX PHARMACEUTICALS, INC. (US) 1988-11-17 EP claimed
WO-1988003805-A1 PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS CHEMEX PHARMACEUTICALS, INC. (US) 1988-06-02 WO claimed
JP-61085379-A None JP disclosed
US-20260138964-A1 PREPARATION OF PHENETHYLAMINES AND CATHINONES AND STEREOISOMERS THEREOF AND PRECURSORS THEREOF TRANSCEND THERAPEUTICS, INC. (US) 2026-05-21 US disclosed
US-20260138964-A1 PREPARATION OF PHENETHYLAMINES AND CATHINONES AND STEREOISOMERS THEREOF AND PRECURSORS THEREOF TRANSCEND THERAPEUTICS, INC. (US) 2026-05-21 US disclosed
EP-4731211-A1 ALLYL- AND PROPARGYLAMINE-TYPE PHENETHYLAMINES AND TRYPTAMINES FOR TREATING MEDICAL DISORDERS Definium Therapeutics US, Inc. (US) 2026-04-29 EP disclosed
US-20250312309-A1 ALLYL-AND PROPARGYLAMINE-TYPE PHENETHYLAMINES AND TRYPTAMINES FOR TREATING MEDICAL DISORDERS Mind Medicine, Inc. (US) 2025-10-09 US disclosed
EP-4605385-A1 PREPARATION OF PHENETHYLAMINES AND CATHINONES AND STEREOISOMERS THEREOF AND PRECURSORS THEREOF Transcend Therapeutics, Inc. (US) 2025-08-27 EP disclosed
EP-4605385-A1 PREPARATION OF PHENETHYLAMINES AND CATHINONES AND STEREOISOMERS THEREOF AND PRECURSORS THEREOF Transcend Therapeutics, Inc. (US) 2025-08-27 EP disclosed
US-20250179042-A1 USE OF DEUTERATED EMPATHOGENS AS THERAPEUTIC AGENTS ALEXANDER SHULGIN RES INSTITUTE INC (US) 2025-06-05 US disclosed
EP-4284789-B1 PROCESS FOR THE PREPARATION OF 3,4-METHYLENEDIOXYPROPIOPHENONE ENDURA SPA (IT) 2025-04-16 EP disclosed
EP-4284789-B1 PROCESS FOR THE PREPARATION OF 3,4-METHYLENEDIOXYPROPIOPHENONE ENDURA SPA (IT) 2025-04-16 EP disclosed
EP-4284789-C0 PROCESS FOR THE PREPARATION OF 3,4-METHYLENEDIOXYPROPIOPHENONE ENDURA SPA (IT) 2025-04-16 EP disclosed
US-12234216-B2 Isotopologues salts, crystalline forms, stereoisomers, of methylone and ethylone and methods of use thereof TERRAN BIOSCIENCES INC. (US) 2025-02-25 US disclosed
US-12221428-B2 Use of deuterated empathogens as therapeutic agents ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. (US) 2025-02-11 US disclosed
WO-2024263978-A1 ALLYL- AND PROPARGYLAMINE-TYPE PHENETHYLAMINES AND TRYPTAMINES FOR TREATING MEDICAL DISORDERS Mind Medicine, Inc. (US) 2024-12-26 WO disclosed
US-20240425471-A1 Process For The Preparation Of 3,4-Methylenedioxypropiophenone ENDURA S.P.A. (IT) 2024-12-26 US disclosed
US-20240425471-A1 Process For The Preparation Of 3,4-Methylenedioxypropiophenone ENDURA S.P.A. (IT) 2024-12-26 US disclosed
US-20240425471-A1 Process For The Preparation Of 3,4-Methylenedioxypropiophenone ENDURA S.P.A. (IT) 2024-12-26 US disclosed
US-20240374558-A1 PREPARATION OF PHENETHYLAMINES AND CATHINONES AND STEREOISOMERS THEREOF AND PRECURSORS THEREOF TRANSCEND THERAPEUTICS, INC. (US) 2024-11-14 US disclosed
US-20240374558-A1 PREPARATION OF PHENETHYLAMINES AND CATHINONES AND STEREOISOMERS THEREOF AND PRECURSORS THEREOF TRANSCEND THERAPEUTICS, INC. (US) 2024-11-14 US disclosed
US-20240351993-A1 Use of Deuterated Empathogens as Therapeutic Agents ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. 2024-10-24 US disclosed
US-20240327372-A1 PREPARATION OF PHENETHYLAMINES AND CATHINONES AND STEREOISOMERS THEREOF AND PRECURSORS THEREOF TRANSCEND THERAPEUTICS, INC. (US) 2024-10-03 US disclosed
US-20240327372-A1 PREPARATION OF PHENETHYLAMINES AND CATHINONES AND STEREOISOMERS THEREOF AND PRECURSORS THEREOF TRANSCEND THERAPEUTICS, INC. (US) 2024-10-03 US disclosed
US-20240294488-A1 ISOTOPOLOGES, SALTS, CRYSTALLINE FORMS, STEREOISOMERS, OF METHYLONE AND ETHYLONE AND METHODS OF USE THEREOF TERRAN BIOSCIENCES INC (US) 2024-09-05 US disclosed
US-12043605-B2 Deuterated empathogens ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. (US) 2024-07-23 US disclosed
US-12043605-B2 Deuterated empathogens ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. (US) 2024-07-23 US disclosed
US-12043605-B2 Deuterated empathogens ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. (US) 2024-07-23 US disclosed
EP-4392028-A1 DEUTERATED EMPATHOGENS Alexander Shulgin Research Institute, Inc. (US) 2024-07-03 EP disclosed
WO-2024086218-A1 PREPARATION OF PHENETHYLAMINES AND CATHINONES AND STEREOISOMERS THEREOF AND PRECURSORS THEREOF TRANSCEND THERAPEUTICS, INC. (US) 2024-04-25 WO disclosed
WO-2024086218-A1 PREPARATION OF PHENETHYLAMINES AND CATHINONES AND STEREOISOMERS THEREOF AND PRECURSORS THEREOF TRANSCEND THERAPEUTICS, INC. (US) 2024-04-25 WO disclosed
US-20240124411-A1 Deuterated Empathogens ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. 2024-04-18 US disclosed
CN-113490659-B Improved and economically viable process for preparing aryl ketones 安西娅芳香剂私人有限公司 2024-03-29 CN disclosed
EP-4284789-A1 PROCESS FOR THE PREPARATION OF 3,4-METHYLENEDIOXYPROPIOPHENONE ENDURA S.p.A. (IT) 2023-12-06 EP disclosed
EP-4284789-A1 PROCESS FOR THE PREPARATION OF 3,4-METHYLENEDIOXYPROPIOPHENONE ENDURA S.p.A. (IT) 2023-12-06 EP disclosed
EP-4284789-A1 PROCESS FOR THE PREPARATION OF 3,4-METHYLENEDIOXYPROPIOPHENONE ENDURA S.p.A. (IT) 2023-12-06 EP disclosed
CN-117015533-A Method for preparing 3, 4-methylenedioxypropiophenone 恩德拉股份公司 2023-11-07 CN disclosed
CN-117015533-A Method for preparing 3, 4-methylenedioxypropiophenone 恩德拉股份公司 2023-11-07 CN disclosed
CN-117015533-A Method for preparing 3, 4-methylenedioxypropiophenone 恩德拉股份公司 2023-11-07 CN disclosed
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 US disclosed
US-20230192642-A1 ISOTOPOLOGUES SALTS, CRYSTALLINE FORMS, STEREOISOMERS, OF METHYLONE AND ETHYLONE AND METHODS OF USE THEREOF TERRAN BIOSCIENCES INC. 2023-06-22 US disclosed
US-20230192642-A1 ISOTOPOLOGUES SALTS, CRYSTALLINE FORMS, STEREOISOMERS, OF METHYLONE AND ETHYLONE AND METHODS OF USE THEREOF TERRAN BIOSCIENCES INC. 2023-06-22 US disclosed
US-20230192642-A1 ISOTOPOLOGUES SALTS, CRYSTALLINE FORMS, STEREOISOMERS, OF METHYLONE AND ETHYLONE AND METHODS OF USE THEREOF TERRAN BIOSCIENCES INC. 2023-06-22 US disclosed
US-11680062-B2 3,4-methylenedioxyphenylimidazolylethanonexime ether derivative, preparation method and use thereof, and drug for the treatment of Alzheimer's disease NORTHWEST A & F UNIVERSITY (CN) 2023-06-20 US disclosed
US-20230159503-A1 3,4-METHYLENEDIOXYPHENYLIMIDAZOLYLETHANONEXIME ETHER DERIVATIVE, PREPARATION METHOD AND USE THEREOF, AND DRUG FOR THE TREATMENT OF ALZHEIMER'S DISEASE NORTHWEST A & F UNIVERSITY (CN) 2023-05-25 US disclosed
WO-2023081403-A1 ISOTOPOLOGES, SALTS, CRYSTALLINE FORMS, STEREOISOMERS, OF METHYLONE AND ETHYLONE AND METHODS OF USE THEREOF TERRAN BIOSCIENCES INC. (US) 2023-05-11 WO disclosed
WO-2023081403-A1 ISOTOPOLOGES, SALTS, CRYSTALLINE FORMS, STEREOISOMERS, OF METHYLONE AND ETHYLONE AND METHODS OF USE THEREOF TERRAN BIOSCIENCES INC. (US) 2023-05-11 WO disclosed
WO-2023028091-A1 DEUTERATED EMPATHOGENS ALEXANDER SHULGIN RESEARCH INSTITUTE (US) 2023-03-02 WO disclosed
US-11518727-B2 Commercially viable process for preparation of aryl ketones ANTHEA AROMATICS PRIVATE LIMITED (IN) 2022-12-06 US disclosed
US-11518727-B2 Commercially viable process for preparation of aryl ketones ANTHEA AROMATICS PRIVATE LIMITED (IN) 2022-12-06 US disclosed
WO-2022162223-A1 PROCESS FOR THE PREPARATION OF 3,4-METHYLENEDIOXYPROPIOPHENONE ENDURA S.P.A. (IT) 2022-08-04 WO disclosed
WO-2022162223-A1 PROCESS FOR THE PREPARATION OF 3,4-METHYLENEDIOXYPROPIOPHENONE ENDURA S.P.A. (IT) 2022-08-04 WO disclosed
WO-2022162223-A1 PROCESS FOR THE PREPARATION OF 3,4-METHYLENEDIOXYPROPIOPHENONE ENDURA S.P.A. (IT) 2022-08-04 WO disclosed
WO-2022161628-A1 PROCESS FOR THE PREPARATION OF 3,4-METHYLENEDIOXYPROPIOPHENONE ENDURA S.P.A. (IT) 2022-08-04 WO disclosed
WO-2022161628-A1 PROCESS FOR THE PREPARATION OF 3,4-METHYLENEDIOXYPROPIOPHENONE ENDURA S.P.A. (IT) 2022-08-04 WO disclosed
WO-2022161628-A1 PROCESS FOR THE PREPARATION OF 3,4-METHYLENEDIOXYPROPIOPHENONE ENDURA S.P.A. (IT) 2022-08-04 WO disclosed
CN-114599355-A Method for treating psychological and cerebral diseases 马里兰大学巴尔的摩分校 2022-06-07 CN disclosed
US-20220169588-A1 AN IMPROVED AND COMMERCIALLY VIABLE PROCESS FOR PREPARATION OF ARYL KETONES ANTHEA AROMATICS PRIVATE LIMITED (IN) 2022-06-02 US disclosed
US-20220169588-A1 AN IMPROVED AND COMMERCIALLY VIABLE PROCESS FOR PREPARATION OF ARYL KETONES ANTHEA AROMATICS PRIVATE LIMITED (IN) 2022-06-02 US disclosed
WO-2022097622-A1 ODOR ANALYZING DEVICE, ODOR ANALYSIS METHOD, AND ODOR ANALYSIS PROGRAM 株式会社レボーン 2022-05-12 WO disclosed
EP-3931173-A1 AN IMPROVED AND COMMERCIALLY VIABLE PROCESS FOR PREPARATION OF ARYL KETONES Anthea Aromatics Private Limited (IN) 2022-01-05 EP disclosed
CN-113490659-A Improved and economically viable process for preparing aryl ketones 安西娅芳香剂私人有限公司 2021-10-08 CN disclosed
WO-2021161083-A1 AN EFFICIENT PROCESS FOR PREPARATION OF ACYL DERIVATIVES OF ALKYLENEDIOXYBENZENES ANTHEA AROMATICS PRIVATE LIMITED (IN) 2021-08-19 WO disclosed
WO-2021161083-A1 AN EFFICIENT PROCESS FOR PREPARATION OF ACYL DERIVATIVES OF ALKYLENEDIOXYBENZENES ANTHEA AROMATICS PRIVATE LIMITED (IN) 2021-08-19 WO disclosed
WO-2021085321-A1 RESIN COMPOSITION, RESIN SHEET, CURED FILM, METHOD FOR MANUFACTURING CURED FILM, SEMICONDUCTOR DEVICE, ORGANIC EL DISPLAY DEVICE, AND DISPLAY DEVICE 東レ株式会社 2021-05-06 WO disclosed
EP-3448843-B1 ARYL BETA DIKETONES AND THEIR USE A ODORANTS GIVAUDAN SA (CH) 2021-02-24 EP disclosed
US-10577298-B2 Aryl beta diketones and their use as odorants GIVAUDAN S.A. (CH) 2020-03-03 US disclosed
US-20190127305-A1 ARYL BETA DIKETONES AND THEIR USE AS ODORANTS GIVAUDAN SA (CH) 2019-05-02 US disclosed
US-10246471-B2 ETP derivatives CITY OF HOPE (US) 2019-04-02 US disclosed
US-20180179151-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF UNIVERSITY OF TSUKUBA (JP) 2018-06-28 US disclosed
CN-104803927-B Chalcone analog of the base containing 2 methyl, 4 oxoquinazolin 6 and its production and use 首都师范大学 2017-11-07 CN disclosed
WO-2017186846-A1 ARYL BETA DIKETONES AND THEIR USE A ODORANTS GIVAUDAN SA (CH) 2017-11-02 WO disclosed
WO-2016172631-A2 SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2016-10-27 WO disclosed
CN-104803927-A Chalcone analogue containing 2-methyl-4-oxo-quinazoline-6-base, and preparation method and application thereof UNIV CAPITAL NORMAL 2015-07-29 CN disclosed
CN-104004128-A Photosensitive copolymer, photoresist comprising the copolymer, and method of forming an electronic device ROHM & HAAS ELECT MAT 2014-08-27 CN disclosed
US-20130196978-A1 ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF CHIESI FARMACEUTICI S.P.A. (IT) 2013-08-01 US disclosed
CN-102438991-A Carbinol compounds having a heterocyclic linker KOWA CO 2012-05-02 CN disclosed
US-8153634-B2 Carbinol derivatives having cyclic linker KOWA COMPANY, LTD. (JP) 2012-04-10 US disclosed
CN-102105452-A Substituted carbinol compound having cyclic linker KOWA CO 2011-06-22 CN disclosed
EP-2281817-A1 SUBSTITUTED CARBINOL COMPOUND HAVING CYCLIC LINKER Kowa Company, Ltd. (JP) 2011-02-09 EP disclosed
US-20100048610-A1 CARBINOL DERIVATIVES HAVING CYCLIC LINKER KOWA COMPANY, LTD. (JP) 2010-02-25 US disclosed
US-7645781-B2 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives PFIZER INC (US) 2010-01-12 US disclosed
EP-1304324-B1 SEROTONIN REUPTAKE INHIBITORS DAINIPPON SUMITOMO PHARMA CO (JP) 2007-10-03 EP disclosed
US-20070015801-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives THOMAS RICHARD C 2007-01-18 US disclosed
EP-1054887-B1 BICYCLIC PYRIDINE AND PYRIMIDINE DERIVATIVES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS AMGEN INC (US) 2006-04-12 EP disclosed
EP-1638909-A2 PROCESS FOR PREPARING ALKOXY- AND ARYLOXY-PHENOLS ENDURA S.p.A. (IT) 2006-03-29 EP disclosed
WO-2004092106-A2 PROCESS FOR PREPARING ALKOXY- AND ARYLOXY-PHENOLS ENDURA S.P.A. (IT) 2004-10-28 WO disclosed
EP-1421071-A2 SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS NOVO NORDISK A/S (DK) 2004-05-26 EP disclosed
EP-1140894-B1 PROCESS FOR THE SYNTHESIS OF 5-(ALPHA -HYDROXYALKYL) BENZO 1, 3]DIOXOLS ENDURA SPA (IT) 2003-12-17 EP disclosed
US-6583154-B1 Neuropeptide Y antagonist; pyrrolo-(3,2-b)pyridines and pyrrolo-(3,2-d)pyrimidines AMGEN INC. 2003-06-24 US disclosed
WO-2003004480-A2 SUBSTITUTED PIPERAZINE AND DIAZEPANES AS HISTAMINE H3 RECEPTOR AGONISTS NOVO NORDISK A/S (DK) 2003-01-16 WO disclosed
US-6342613-B1 REACTING PYROCATECHOL WITH DIHALO- OR DI-ALKOXYALKANE, ACYLATING BENZO(1,3)DIOXOLE DERIVATIVE FORMED IN PRESENCE OF CATALYST, REDUCING TO 5-(ALPHA-HYDROXYALKYL)BENZO(1,3)DIOXOLE ENDURA S.P.A. (IT) 2002-01-29 US disclosed
EP-1140894-A1 PROCESS FOR THE SYNTHESIS OF 5-(ALPHA -HYDROXYALKYL) BENZO 1, 3]DIOXOLS ENDURA S.p.A. (IT) 2001-10-10 EP disclosed
US-6187777-B1 PYRROLO(3,2-D)PYRIMIDINE DERIVATIVES; NEUROPEPTIDE Y AND CORTICOTROPIN RELEASING FACTOR MODULATORS; DIETETICS; ANTIDIABETIC, ANTIINFLAMMATORY, AND ANTITUMOR AGENTS AMGEN INC. 2001-02-13 US disclosed
EP-1054887-A1 BICYCLIC PYRIDINE AND PYRIMIDINE DERIVATIVES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS Amgen Inc. (US) 2000-11-29 EP disclosed
WO-2000040575-A1 PROCESS FOR THE SYNTHESIS OF 5-(α -HYDROXYALKYL) BENZO[1, 3]DIOXOLS ENDURA S.P.A. (IT) 2000-07-13 WO disclosed
WO-1999040091-A1 BICYCLIC PYRIDINE AND PYRIMIDINE DERIVATIVES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS AMGEN INC. (US) 1999-08-12 WO disclosed
WO-1996039133-A1 NOVEL N-SUBSTITUTED-2-AMINO-3',4'-METHYLENE-DIOXYPROPIOPHENONES NEUROBIOLOGICAL TECHNOLOGIES, INC. (US) 1996-12-12 WO disclosed
EP-0589039-A1 TRIPHENYLETHYLENE DERIVATIVE AND PHARMACEUTICAL PREPARATION CONTAINING THE SAME Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1994-03-30 EP disclosed
EP-0290442-A4 PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS. CHEMEX PHARMACEUTICALS INC (US) 1990-07-03 EP disclosed
EP-0290442-A1 PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS CHEMEX PHARMACEUTICALS, INC. (US) 1988-11-17 EP disclosed
WO-1988003805-A1 PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS CHEMEX PHARMACEUTICALS, INC. (US) 1988-06-02 WO disclosed
JP-S6185379-A 3',4'-METHYLENEDIOXYPROPIOPHENONE DERIVATIVE AND CENTRAL MUSCULE RELAXANT CONTAINING SAID DERIVATIVE AS ACTIVE COMPONENT TOKYO TANABE CO LTD 1986-04-30 JP disclosed
EP-0163537-A1 1-Propanone derivatives and pharmaceutical compositions containing same TOKYO TANABE COMPANY LIMITED (JP) 1985-12-04 EP disclosed
US-4058607-A DIHALOVINYL DIALKYL PHOSPHATE, 1,3-BENZODIOXOLES AIRWICK INDUSTRIES, INC. (US) 1977-11-15 US disclosed
US-3962415-A Insecticide evaporator comprising DDVP with synergized benzodioxole compound as stabilizer AIRWICK INDUSTRIES, INC. (US) 1976-06-08 US disclosed
US-3946040-A JUVENILE HORMONE ACTIVITY, INSECTICIDES HOFFMANN-LA ROCHE INC. (US) 1976-03-23 US disclosed
JP-S06185379-A 0001-01-01 JP disclosed
JP-S06185379-A 0001-01-01 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (24 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10246471-B2 ETP derivatives ETV6, ETV1, ELP1 ATM 1053/4885MEN1 3286/4885KMT2A 2611/4885
US-20180179151-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF HCRTR2, HCRTR1, NPSR1 ATM 4791/4885MEN1 2469/4885KMT2A 234/4885
US-20230159503-A1 3,4-METHYLENEDIOXYPHENYLIMIDAZOLYLETHANONEXIME ETHER DERIVATIVE, PREPARATION METHOD AND USE THEREOF, AND DRUG FOR THE TREATMENT OF ALZHEIMER'S DISEASE NOS3, CYP51A1, NOS1 ATM 1051/4885MEN1 3755/4885KMT2A 1942/4885
US-10577298-B2 Aryl beta diketones and their use as odorants CBR3, CBR1, CHRM3 ATM 2800/4885MEN1 3913/4885KMT2A 627/4885
US-20190127305-A1 ARYL BETA DIKETONES AND THEIR USE AS ODORANTS CBR3, CBR1, CHRM3 ATM 2800/4885MEN1 3913/4885KMT2A 627/4885
US-20130196978-A1 ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF CHRM3, CHRM1, CHRNG ATM 771/4885MEN1 4121/4885KMT2A 1874/4885
US-20250179042-A1 USE OF DEUTERATED EMPATHOGENS AS THERAPEUTIC AGENTS SLC18A2, SLC6A3, GAP43 ATM 4111/4885MEN1 2108/4885KMT2A 1902/4885
US-12234216-B2 Isotopologues salts, crystalline forms, stereoisomers, of methylone and ethylone and methods of use thereof PYGB, NR3C2, CYP11B1 ATM 1490/4885MEN1 1408/4885KMT2A 1583/4885
US-11518727-B2 Commercially viable process for preparation of aryl ketones CYP2B6, CYP1B1, CYP1A1 ATM 1427/4885MEN1 4527/4885KMT2A 1373/4885
US-20240327372-A1 PREPARATION OF PHENETHYLAMINES AND CATHINONES AND STEREOISOMERS THEREOF AND PRECURSORS THEREOF PNMT, COMT, CYP2C19 ATM 2731/4885MEN1 1168/4885KMT2A 345/4885
US-12043605-B2 Deuterated empathogens SLC18A2, SLC6A3, GAP43 ATM 4263/4885MEN1 2182/4885KMT2A 1364/4885
US-20230192642-A1 ISOTOPOLOGUES SALTS, CRYSTALLINE FORMS, STEREOISOMERS, OF METHYLONE AND ETHYLONE AND METHODS OF USE THEREOF PYGB, NR3C2, CYP11B1 ATM 1490/4885MEN1 1408/4885KMT2A 1583/4885
US-20260138964-A1 PREPARATION OF PHENETHYLAMINES AND CATHINONES AND STEREOISOMERS THEREOF AND PRECURSORS THEREOF DMPK, CHKB, TTK ATM 1666/4885MEN1 482/4885KMT2A 1247/4885
US-11680062-B2 3,4-methylenedioxyphenylimidazolylethanonexime ether derivative, preparation method and use thereof, and drug for the treatment of Alzheimer's disease NOS3, CYP51A1, NOS1 ATM 1051/4885MEN1 3755/4885KMT2A 1942/4885
US-20100048610-A1 CARBINOL DERIVATIVES HAVING CYCLIC LINKER NR1H2, NR1H3, LDLR ATM 2086/4885MEN1 3823/4885KMT2A 2383/4885
US-12221428-B2 Use of deuterated empathogens as therapeutic agents SLC18A2, SLC6A3, GAP43 ATM 4111/4885MEN1 2108/4885KMT2A 1902/4885
US-20220169588-A1 AN IMPROVED AND COMMERCIALLY VIABLE PROCESS FOR PREPARATION OF ARYL KETONES CYP2B6, CYP1B1, CYP2E1 ATM 1820/4885MEN1 4669/4885KMT2A 1341/4885
US-20240294488-A1 ISOTOPOLOGES, SALTS, CRYSTALLINE FORMS, STEREOISOMERS, OF METHYLONE AND ETHYLONE AND METHODS OF USE THEREOF CYP11B1, PYGB, CYP11B2 ATM 1692/4885MEN1 1881/4885KMT2A 2206/4885
US-20240351993-A1 Use of Deuterated Empathogens as Therapeutic Agents SLC18A2, SLC6A3, GAP43 ATM 4111/4885MEN1 2108/4885KMT2A 1902/4885
US-20070015801-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives OXA1L, AADAC, MT-ND5 ATM 4474/4885MEN1 3522/4885KMT2A 1273/4885
US-20240425471-A1 Process For The Preparation Of 3,4-Methylenedioxypropiophenone PF4, FGB, PFN1 ATM 4233/4885MEN1 4397/4885KMT2A 3450/4885
US-20240124411-A1 Deuterated Empathogens SLC18A2, SLC6A3, GAP43 ATM 4263/4885MEN1 2182/4885KMT2A 1364/4885
US-20240374558-A1 PREPARATION OF PHENETHYLAMINES AND CATHINONES AND STEREOISOMERS THEREOF AND PRECURSORS THEREOF PNMT, COMT, CYP2C19 ATM 2731/4885MEN1 1168/4885KMT2A 345/4885
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSL, CTSV ATM 2654/4885MEN1 4306/4885KMT2A 3383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.